March 28, 2022 Digital Health Technologies for Remote Data Acquisition in Clinical Investigations C-Path thanks and commends FDA for inviting public comments as part of the creation of a guidance document for Digital Health...
March 11, 2022 Leveraging Real-World Data for EMA Qualification of a Model-Based Biomarker Tool to Optimize Type-1 Diabetes Prevention Studies The development of therapies to prevent or delay the onset of type 1 diabetes (T1D) remains challenging, and there is a lack of qu
April 29, 2022 View Now | C-Path in Europe: Moving Global Regulatory Science Forward In support of C-Path’s mission to catalyze innovation that accelerates the path to a healthier world, we’re excited
C-Path Receives Qualification Opinion from EMA on Type 1 Diabetes Biomarker Initiative TUCSON, Ariz., April 5, 2022 — Critical Path Institute’s (C-Path) Type 1 Diabetes Consortium (T1DC) today announced that the E
New logo! Rare Disease Cures Accelerator-Data and Analytics Platform has a new look! C-Path’s RDCA-DAP team is excited to unveil its new logo for the Rare Disease Cures Accelerator-Data and Analytics Platform
Longtime Pharmaceutical Executive to Lead C-Path’s Sickle Cell Disease Consortium TUCSON, Ariz., April 14, 2022 – Critical Path Institute (C-Path) has named Sergey Rakhilin, Ph.D., as Executive Director of its
March 7, 2022 eTRANSAFE: Building a sustainable framework to share reproducible drug safety knowledge with the public domain
May 23, 2022-February 8, 2024 View Now | International 2022 Drug-induced Kidney Injury Biomarker Workshop On May 23-24 the International Drug-induced Kidney Injury Biomarker Workshop will be held in a virtual format. Critical Path Insti